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B-Cell-Directed Therapy for Inflammatory Skin Diseases
Angela Nagel1, Michael Hertl1 and Ru¨diger Eming1
The basic understanding of inflammatory dermatoses and autoimmune-mediated skin disorders has greatly
advanced and broadened our understanding of underlying immune mechanisms that shape the complex
network of chronic inflammation and autoimmunity. The new treatment options for psoriasis exemplify how
new insights into (auto)immune responses, especially the role and function of various immune cells and
proinflammatory cytokines, may lead to new therapeutic strategies. The concept of targeting B cells in
autoimmune-mediated disorders is closely related to the discovery of autoantibodies and their cellular origin.
However, the appreciation of B cells in autoimmunity has significantly changed and is not limited to their role as
progenitors of autoantibody secreting plasma cells. Recent investigations of various inflammatory skin diseases,
that is, autoimmune blistering disorders, collagen vascular diseases, and atopic dermatitis, actually support the
concept that B cells might be as important as T cells in the etiopathogenesis of these disorders. The striking
clinical improvement seen in patients with rheumatoid arthritis following B-cell depletion with the anti-CD20
mAb rituximab has tremendously catalyzed the interest in B-cell-targeted therapies in different autoimmune
diseases. Future translational and clinical investigations are mandatory to precisely define the role and the
contribution of impaired B-cell function in (auto)immune-mediated skin diseases.
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INTRODUCTION
B cells play an important role in innate
and adaptive immune processes. The
aberrant regulation and activation of B
cells result in a variety of chronic
inflammatory and autoimmune-mediated
disorders, respectively. In addition to
their function as progenitors of (auto)-
antibody-secreting plasma cells, B cells
contribute to (auto)immune responses
by various antibody (Ab)-independent
mechanisms. They are capable of
regulating T-cell activation and expan-
sion by antigen presentation and
expression of costimulatory signals
(Mason, 1996). Moreover, several
mouse models of different autoimmune
diseases revealed the significant role of
B cells in disease progression by
release of cytokines and chemokines,
respectively (Martin and Chan, 2004).
Membrane-bound lymphotoxin a/b on
the surface of B cells is effective in
activating the lymphotoxin b-receptor
on stromal cells contributing to the
formation of organized lymphoid tis-
sues at sites of chronic inflammation,
termed lymphoid neogenesis (Browning,
2006). In rheumatoid arthritis (RA) or
primary Sjo¨gren’s syndrome (pSS),
these ectopic lymphoid structures have
been shown to develop a high degree
of organization including distinct T-
and B-cell zones, germinal center for-
mation, and high endothelial venules,
providing additional trafficking oppor-
tunities (Bombardieri et al., 2007;
Timmer et al., 2007). The contribution
of B cells to the complex pathogenesis
of autoimmune diseases has become
evident and better characterized by the
recent application of B-cell-targeting
therapeutic agents, especially the chi-
meric anti-CD20 Ab rituximab (Ritux-
an; Genentech Inc., Biogen Idec Inc.;
and MabThera; Roche Inc.).
B CELLS IN DERMATOLOGICAL
AUTOIMMUNE DISORDERS
Autoantibodies have been considered
the hallmark of B-cell contribution to
autoimmune diseases. There are a few
autoimmune disorders in which the
pathogenic relevance of the autoanti-
bodies is well characterized; among
those are autoimmune bullous disor-
ders, particularly pemphigus and the
pemphigoids. In most autoimmune
diseases, such as systemic lupus er-
ythematosus (SLE), systemic sclerosis
(SSc), and dermatomyositis, autoanti-
bodies are not considered to play a
direct role in disease pathogenesis, but
provide clinically relevant diagnostic
and prognostic criteria. Antinuclear
antibodies serve as a sensitive diagnos-
tic marker for SLE, but are also ob-
served in a variety of other collagen
vascular disorders, and their titers do
not correlate with disease severity. It is
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noteworthy that antinuclear antibodies
are detectable in SLE patients before
disease manifestation in the same way
as circulating autoantibodies against
desmoglein 1 (dsg1) are detectable in
endemic forms of pemphigus foliaceus
(PF) in Brazil (Fogo Selvagem) and
Tunesia before disease onset (Kallel
Sellami et al., 2004; Hilario-Vargas
et al., 2006). These findings raise the
question: to what extent do circulating
autoantibodies contribute directly to
disease manifestation or point to the
presence of autoreactive B cells? How-
ever, additional triggering events, that
is, infections and inflammation, may
drive the initially nonpathogenic im-
mune response to autoaggressive
chronic immune events. A recent study
in a mouse model of pemphigus
vulgaris (PV) suggests that a concerted
effect of monoclonal dsg3-reactive IgG
autoantibodies is required to induce
blister formation, leading to the hy-
pothesis that synergistic effects of var-
ious autoantibodies are necessary to
induce disease manifestation (Kawasaki
et al., 2006). The pathogenicity of
autoantibodies in autoimmune dis-
orders is not restricted to direct binding
to the target structure leading to its loss
of function, but includes indirect effects
such as complement activation or the
formation and deposition of circulating
immune complexes that cause severe
organ damage, including glomerulone-
phritis and vasculitis. In this context,
polymorphisms of the low- and high-
affinity Fc receptors were described to
be associated with distinct autoim-
mune disorders, such as SLE or im-
mune-mediated thrombocytopenia
(Binstadt et al., 2003). B cells undergo
a complex development from hemato-
poietic precursors to mature short- and
long-lived plasma cells. Wardemann
et al. (2003) demonstrated that 50–70%
of human B-cell precursors exhibit
autoreactive antibodies, although the
mature B-cell compartment contains
only few self-reactive B cells. Self-
reactive (autoreactive) B cells are de-
leted at certain stages of B cell devel-
opment. The study by Wardemann
et al. (2003) suggests that the depletion
of these autoreactive B cells occurs at
the stage of immature B cells and at the
transition of new emigrant (i.e. leaving
the bone marrow) and mature B cells in
the periphery. A recent study by
Yurasov et al. (2005) revealed that in
SLE patients 25–50% of the naı¨ve
mature B-cell population produce auto-
antibodies, indicating that defective
regulatory mechanisms at early stages
of B-cell development account for loss
of self-tolerance. The successful use of
B-cell-depleting therapies in (auto)im-
mune-mediated skin disorders that are
not considered primarily B cell depen-
dent, such as atopic dermatitis, points
to the important function of B cells
beyond the secretion of (auto)antibo-
dies. Although autoantibodies have not
been identified in psoriasis and psor-
iasis arthritis, recent investigations
showed ectopic lymphoid neogenesis
in synovial tissues of psoriasis arthritis
patients, suggesting an effective role of
B cells and probably their secreted
signaling molecules in disease progres-
sion (Canete et al., 2007). In SSc, there
is recent evidence that early-activated
B cells interact with both endothelial
cells and fibroblasts through the
release of (auto)antibodies and cyto-
kines such as IL-6, promoting fibrosis
(Sakkas et al., 2006). The release of
various pro- and anti-inflammatory
cytokines by B cells is considered to
contribute to the inflammatory (auto)-
immune response in several derma-
tological disorders, for example, psor-
iasis, atopic dermatitis, and SSc,
although the precise function of B cells
in the pathogenesis of these diseases is
not yet completely understood. These
findings suggest that B-cell-directed
therapy might provide an important
therapeutic opportunity for a variety
of dermatological diseases.
STRATEGIES OF B-CELL-DIRECTED
THERAPY
Different approaches to targeting B-cell
function are currently introduced,
including the development of (i) anti-
bodies that are directed against surface
markers, which are preferentially ex-
pressed by B cells (that is, CD20,
CD22) and (ii) inhibitors of survival
and signaling factors that are crucial for
B-cell activation (B-cell-activating fac-
tor (BAFF)/ a proliferation-inducing
ligand (APRIL)) and T cell–B cell inter-
action (CD40/CD40L).
Antibodies against cell-surface markers
Anti-CD20 Ab (rituximab). Among the
various mAbs used for targeting B cells,
the chimeric IgG1 anti-CD20 Ab, ritux-
imab, has gained major clinical
application. CD20 is a four trans-
membrane phosphoprotein that is ex-
pressed on most B cells from the late
pre-B-cell stage until terminal plasma
cell differentiation (Cragg et al., 2005).
Originally, the lack of CD20 expression
in autoantibody-secreting plasma cells
questioned the usefulness of employing
rituximab in autoimmune diseases.
Moreover, the physiological function
of the CD20 receptor remains obscure,
partly due to its still unknown ligand.
The successful treatment of B-cell
lymphomas catalyzed the application of
the anti-CD20 mAb rituximab in various,
mostly autoantibody-mediated, autoim-
mune disorders. In 2007, rituximab was
approved by the FDA for the treatment of
RA patients who demonstrated an inade-
quate response to antitumor necrosis
factor (TNF)-therapy. Rituximab induces
B-cell lysis mainly by Ab-dependent cell-
mediated cytotoxicity, but complement-
dependent cytotoxicity and direct proa-
poptotic signals are discussed as well,
although recent studies in mouse models
demonstrated a predominant role for Fc-
receptor-mediated effects of anti-CD20
treatment (Uchida et al., 2004).
Depending on the compartment and
the microenvironment, the sensitivity
to anti-CD20 treatment and the kinetics
of B-cell depletion show significant
variations. In human CD20 BAC (bac-
terial artifical chromosome)-transgenic
mice, peritoneal B1 cells and germinal
center B cells demonstrate relative
resistance to anti-CD20 administration,
whereas circulating B cells are rapidly
depleted (Gong et al., 2005; Hamagu-
chi et al., 2005). Moreover, marginal
zone B cells are less affected by anti-
CD20 depletion compared with folli-
cular B cells in the spleen. Vugmeyster
et al. (2005) demonstrated in cynomol-
gus monkeys that the depletion of
splenic B cells was more profound
compared with lymph node B cells
after treatment with the fully huma-
nized anti-CD20 Ab PRO70769. The
contribution of the different B-cell
populations to human autoimmune
disorders is largely unknown. There-
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fore, it is unclear whether the prefer-
ential depletion of peripheral blood-
naı¨ve B cells after rituximab therapy
has any implication for its clinical use
in autoimmune diseases. In humans,
the effect of anti-CD20 Ab treatment on
tissue B-cell populations has been
investigated in RA and pSS (Pers
et al., 2007; Thurlings et al., 2008;
Vos et al., 2007). One month after
rituximab treatment, 3 out of 17 RA
patients demonstrated a complete de-
pletion of synovial B cells, 11 patients
showed a partial depletion, and 3
patients did not show any synovial B
cells before rituximab treatment (Vos
et al., 2007). The same group investi-
gated the effect of rituximab on the
inflammatory infiltrate in synovial tis-
sue of 24 RA patients (Thurlings et al.,
2008). One month after rituximab,
there was a significant decrease but
not a complete depletion of synovial B
cells in all patients, followed by a
further reduction of B cells 16 weeks
after treatment in some patients. At that
time point, the authors noticed a
pronounced decrease in synovial
macrophages, T cells, and plasma cells,
which partially correlated with the
clinical response (Thurlings et al.,
2008). These early observations suggest
an important role for B cells in sustain-
ing the autoimmune response at the
primary site of inflammation in RA. A
confirmatory study in pSS demon-
strated that in eight patients, rituximab
treatment induced a complete B-cell
depletion in salivary glands that lasted
for up to 24 months after treatment
(Pers et al., 2007). As shown for RA and
SLE, in pemphigus, a rapid and com-
plete depletion of CD19þ circulating B
cells was noticed within days after the
first infusion of rituximab. On average,
depletion of peripheral CD19þ B cells
lasted for 6–9 months but persisted up
to 15 months in some PV patients
(Eming et al., 2008).
Effect of rituximab on non-B-cell
populations in autoimmunity. There is
increasing evidence that in addition to
direct B-cell depletion, rituximab treat-
ment exerts effects on distinct immune
cells like autoreactive T effector cells
(Eming et al., 2008), regulatory T cells
(Sfikakis et al., 2007), and monocyte-
derived macrophages (Toubi et al.,
2007) (Figure 1). Seven SLE patients
with active nephritis were treated
with rituximab (4375 mg m2), and
mRNA expression of genes associated
with regulatory T cells was determined
in peripheral blood mononuclear cells
by real-time PCR (Sfikakis et al., 2007).
In all seven SLE patients, mRNA levels
of the T-regulatory markers interleukin
2 receptor alpha subunit (IL-2R alpha)
(CD25), cytotoxic T-lymphocyte anti-
gen-4 (CTLA-4), glucocorticoid-in-
duced tumor necrosis factor receptor
family-related gene (GITR), forkhead
box P3 (FOXP3), and transforming
growth factor beta (TGF-b) increased
significantly following B-cell depletion,
whereas mRNA expression of the cost-
imulatory molecule, CD40L, was pro-
foundly reduced. The authors found
that increased FOXP3 mRNA levels
persisted in peripheral blood mono-
nuclear cells of patients in clinical
remission, whereas peripheral blood
mononuclear cells from relapsing
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Figure 1. Effects of rituximab in autoantibody-mediated disorders. (a) The mAb rituximab induces the depletion of CD20þ B cells resulting in a decreased
de novo generation of short- and long-lived plasma cells (PC). Secondly, rituximab interrupts the interaction between autoreactive T helper (Th) cells and
antigen-presenting B cells. (b) Rituximab leads to significant reduction of CD40 and CD80 expression on B cells (Tokunaga et al., 2005, 2007) as well as CD69,
ICOS, HLA-DR, and CD40 L expression on CD4þ Th cells (Tokunaga et al., 2007; Sfikakis et al., 2005a, b). Thus, important costimulatory signals, for example,
through the CD40-CD40 L pathway, regulating T-cell–B-cell interactions, are interrupted, preventing the action of autoreactive immune processes (Desai-Mehta
et al., 1996). (c) Rituximab inhibits the release of proinflammatory cytokines such as TNF-a by monocyte-derived macrophages, whereas the secretion of BAFF
and IL-10 is increased. Moreover, IL-10 stimulates the secretion of BAFF in an autocrine/paracrine manner. CD86 surface expression on monocytes/
macrophages (Mo¨) is enhanced (Toubi et al., 2007). (d) Rituximab directly induces CD4þCD25þ regulatory T cells (TReg) identified by increased mRNA
expression of Foxp3, GITR, and CTLA-4 (Vigna-Perez et al., 2006; Sfikakis et al., 2007; Vallerskog et al., 2007).
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patients demonstrated decreasing FOXP3
levels (Sfikakis et al., 2007). A study by
Vallerskog et al. (2007) demonstrated an
increase of both activated CD4þCD25þ
T cells and CD4þ CD25bright FOXP3þ
regulatory T cells in 11 SLE patients after
rituximab therapy. The results of these
studies suggest that modulation of reg-
ulatory T-cell function might contribute
to the clinical effect of rituximab treat-
ment in SLE. In addition to these findings
in SLE, a recent study by Stasi et al.
(2008) suggests a restorative effect of
transient B-cell depletion on abnormal
regulatory T-cell function in idiopathic
thrombocytopenic purpura. In this study,
CD4þ FOXP3þ regulatory T cells from
peripheral blood of 26 idiopathic throm-
bocytopenic purpura patients receiving
rituximab therapy were investigated by
flow cytometry and their suppressive
capacity was analyzed in vitro before
and 3 months after rituximab therapy
(Stasi et al., 2008). In idiopathic throm-
bocytopenic purpura patients who re-
sponded to anti-CD20 Ab treatment, the
authors noticed restored numbers and
a restored regulatory function of
CD4þFOXP3þ T cells compared with
pretreatment data.
The most obvious reason for applying
anti-CD20 Ab treatment in pemphigus is
the removal of precursors of autoanti-
body-secreting plasma cells. Several
lines of evidence point to the important
role of autoreactive CD4þ T cells in the
initiation and perpetuation of autoanti-
body secretion in pemphigus (Wucherp-
fennig et al., 1995; Lin et al., 1997;
Tsunoda et al., 2002; Hertl et al., 2006).
In this context, the depletion of auto-
reactive B cells as antigen-presenting
cells might exert an indirect effect on
dsg3-specific CD4þ T cells. A recent
study by our group demonstrates a
statistically significant decrease of dsg3-
reactive CD4þ T cells in PV patients on
rituximab treatment (Eming et al., 2008).
In a cohort of 11 PV patients treated with
rituximab (4 375 mg m2), the frequen-
cies of dsg3-reactive, peripheral Th1
(interferon-gþ ) and Th2 (IL-4þ ) cells
were determined over a period of 12
months after rituximab treatment.
Whereas frequencies of total CD3þ
CD4þ T helper cells remained unaf-
fected by rituximab, the frequencies of
autoreactive Th1 and Th2 cells
decreased significantly for 6 and 12
months after therapy, respectively. Inter-
estingly, the frequencies of interferon-gþ
tetanus toxoid-reactive T cells were not
affected, suggesting that dsg3-specific
CD4þ T cells strongly depend on auto-
reactive B cells as antigen-presenting
cells (Eming et al., 2008). This finding is
strengthened by a recent mouse study
providing evidence that B cells contri-
bute to T-cell activation and expansion
(Bouaziz et al., 2007). This report clearly
demonstrated that anti-CD20-mediated
B-cell depletion significantly reduced
CD4þ T-cell responses to self-antigens
in models of collagen-induced arthritis,
autoimmune diabetes (non-obese dia-
betic (NOD) mice), and to pathogens
such as Listeria monocytogenes
(Bouaziz et al., 2007).
Impact of B-cell-depleting therapies on
B-cell function in autoimmune disor-
ders. To date, rituximab has been
investigated in a plethora of autoim-
mune disorders, including RA, SLE,
idiopathic thrombocytopenic purpura,
vasculitides, and several dermatological
disorders (Table 1). Most of the informa-
tion on B-cell function altered by anti-
CD20 Ab treatment in autoimmune
diseases results from clinical trials per-
formed predominantly in RA and from
smaller studies in patients with SLE and
pSS. Although rituximab induces a
profound depletion of circulating B cells,
several studies demonstrated that ritux-
imab does not significantly reduce
serum levels of total IgM, IgG, or IgA
in RA, SLE, or Wegener’s granulomatosis
(Cambridge et al., 2003; Vallerskog
et al., 2007; Ferraro et al., 2008). More-
over, there is no statistically significant
decline in autoantibodies to common
pathogens (cytomegalovirus, Epstein–-
Barr virus) or recall antigens such as
tetanus toxoid after anti-CD20 Ab treat-
ment (Cambridge et al., 2003; Ferraro
et al., 2008). A recent study by Nagel
et al. (Nagel, A, Podstawa E, Eickmann
M, Hertl M, Eming R, Rituximab med-
iates a strong elevation of B cell activat-
ing factor (BAFF) associated with
increased pathogen-specific IgG but not
anti-bodies in pemphigus vulgaris, sub-
mitted) showed an increase in anti-
varicella-zoster-virus-IgG and anti-Ep-
stein–Barr virus-IgG titers in 11 PV
patients on rituximab. Various studies
focused on the relationship between
reconstitution of circulating B-cell sub-
sets and disease relapse after rituximab
therapy (Leandro et al., 2006; Roll et al.,
2006), indicating that B-cell recovery is
associated with an increased number of
B cells expressing a transitional pheno-
type (IgDþ , IgMþ , CD10þ , CD24þ ,
CD38high, and CD27) and with increas-
ing numbers of B cells demonstrating a
plasmablast phenotype (CD27high,
CD38high, CD20, IgD). In RA, Lean-
dro et al. (2006) demonstrated that
disease relapse was associated with a
higher frequency of memory B cells at
the time of B-cell repopulation. A very
interesting aspect of B-cell-directed ther-
apy in autoimmune disorders is the
correlation of autoantibody levels and
disease response. In systemic autoim-
mune disorders, such as RA and SLE, the
relationship between B-cell depletion,
alterations in autoantibody titers, and
clinical response is inconsistent (Cam-
bridge et al., 2006; Cohen et al., 2006).
On the other hand, in organ-specific
autoimmunity (i.e., PV and PF), the
rituximab-induced decline in circulating
IgG autoantibodies mostly correlates
well with clinical remission (Ahmed
et al., 2006, Joly et al., 2007, Eming
et al., 2008). Apparently, autoreactive B
cells in RA and SLE are of pathogenic
relevance besides the production of
autoantibodies probably through their
function as antigen-presenting and cyto-
kine-releasing cells, and B-cell depletion
might exert its clinical effect through
these mechanisms.
Following this line of thought, a
recent study by Simon et al. (2008)
revealed the potential role of B cells in
the pathogenesis of atopic eczema. In
this study, six patients with atopic
dermatitis treated with rituximab
(2 1,000 mg) demonstrated a signifi-
cant reduction of the eczema area and
severity index within 8 weeks following
anti-CD20 Ab treatment (Simon et al.,
2008). Moreover, the authors noticed a
reduction of CD20þ B cell infiltrates as
well as decreased mRNA levels of IL-5
and IL-13 in lesional skin biopsies. These
preliminary findings suggest that B cells
play a crucial role as antigen-presenting
cells and activators of T cells in the
pathogenesis of atopic dermatitis.
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Anti-CD20 Ab therapy in blistering
skin disorders. The first reports of
rituximab treatment in patients with
autoimmune bullous diseases de-
scribed two female patients with para-
neoplastic pemphigus (Borradori
et al., 2001; Heizmann et al., 2001).
Heizmann et al. reported a complete
remission of conjunctival and mucocu-
taneous lesions within 6 months after
rituximab therapy and Borradori et al.
described the rapid improvement of
Table 1. Rituximab in dermatological diseases: treatment schedules and clinical results
Rituximab regimen intravenous dose
(mgm2 body surface area)1 Clinical response Selected references
Primary cutaneous B-cell lymphoma
Single infusion: 375
Weekly: 4 375, 6 375, 8 375
Intralesional therapy: 10–30 mg1 rituximab per
lesion three times weekly repeated every 28 days for
6 months or weekly for 5 consecutive weeks
- without concomitant IS
Partial or mostly complete remission with resolution
of skin lesions
Intralesional therapy: tumor regression even of
lesions that have not been injected
Intralesional therapy is characterized by application
of smaller doses of rituximab, but increased
recurrence rate compared with intravenous therapy
(Heinzerling et al., 2000a, b; Paul et al.,
2001; Bonnekoh et al., 2002; Fink-Puches
et al., 2005; Lacouture et al., 2005;
Roguedas et al., 2005; Kerl et al., 2006;
Nagasaki et al., 2006)
Bullous skin diseases: pemphigus vulgaris including childhood/juvenile pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, bullous
pemphigoid, mucous membrane pemphigoid, and epidermolysis bullosa aquisita
Weekly: 2 375, 4 375
4 375 weekly followed by 1 375 monthly and
later 3-month intervals
4 375 weekly followed by 2 375 biweekly
Two cycles 3 375 weekly followed by
1 2 g/kg body weight IVIg in the fourth week
- with concomitant IS
Partial or complete remission according to strong
improvement of main clinical signs (cutaneous
and mucocutaneous lesions), autoantibody titers,
and reduction of concomitant IS
(Salopek et al., 2002; Cooper et al., 2003;
Goebeler et al., 2003; Dupuy et al., 2004;
Espana et al., 2004; Arin et al., 2005; Kong
et al., 2005; Schmidt et al., 2005, 2006,
2007; Ahmed et al., 2006; Niedermeier
et al., 2006, 2007; Carr and Heffernan,
2007; Crichlow et al., 2007; Joly et al., 2007)
Systemic lupus erythematosus (SLE) including lupus nephritis, neuropsychiatric, and childhood-onset SLE
Single infusion: 100, 375, 1,0001
Weekly: 2 375, 4 375, 4 500
Biweekly: 2 500, 2 750, 2 1,0001
Rarely other doses
- with or without concomitant IS
Partial or complete remission according to
BILAG-, SLAM-, and SLEDAI-scores
Fast improvement of skin and mucocutaneous
lesions
Improvement of lupus nephritis according to
decline in proteinuria
(Anolik et al., 2004; Looney et al., 2004;
Marks et al., 2005; Sfikakis et al., 2005a, b;
Tokunaga et al., 2005, 2007; Smith et al.,
2006; Willems et al., 2006; Jonsdottir et al.,
2008; Ng et al., 2007; Tanaka et al., 2007;
Walsh and Jayne, 2007)
Primary Sjo¨gren’s syndrome including anterior scleritis
Weekly: 2 375, 4 375
- without concomitant IS
Partial or complete remission according to
subjective parameters like fatigue and dryness
or VAS score
Objective parameters like ophtalmological
evaluation or Ab titers were not changed
(Ahmadi-Simab et al., 2005; Pijpe et al.,
2005; Devauchelle-Pensec et al., 2007)
Dermatomyositis including juvenile dermatomyositis
Weekly: 4 100, 4 375
Biweekly: 2 1,0001
- with or without concomitant IS
Partial remission according to reduction of DSSI
and muscle strength deficit
significant improvement of skin lesions
Objective parameters like ophtalmologic evaluation
or Ab titers were not changed
(Levine, 2005; Chung et al., 2007; Cooper
et al., 2007; Dinh et al., 2007)
Antineutrophil cytoplasmatic Ab (ANCA)-associated vasculitis including Churg–Strauss syndrome, microscopic polyangiitis, mixed cryoglobulinemia, and
Wegener’s granulomatosis
Weekly: 2 250, 3 375, 4 375, 4 5001
Biweekly: 2 5001, 2 1,0001
4-weekly: 4 275
- with or without concomitant IS
Partial or complete remission according to strong
improvement of main clinical signs (or BVAS Score)
In some cases, stability of disease manifestation or
rather progression (mainly retro-orbital granulomas)
Decline or stability of ANCA titers
Strong improvement of cutaneous manifestations
(Zaja et al., 2003; Eriksson, 2005; Ferraro
et al., 2005; Kallenbach et al., 2005; Keogh
et al., 2005; Aries et al., 2006; Kaushik et al.,
2006; Keogh et al., 2006; Koukoulaki et al.,
2006; Smith et al., 2006; Visentini et al.,
2007; Walsh and Jayne, 2007)
Atopic eczema
Biweekly: 2 1,0001
- with concomitant IS
Significant improvement of AE lesions according
to reduction of EASI and pruritus score
(Simon et al., 2008)
BILAG, British islet lupus assessment group; BVAS, Birmingham vasculitis activity score; DSSI, dermatomyositis skin severity index; EASI, eczema area and
severitiy index; IS, immunosuppressive treatment; IVIg, intravenous immunoglobulin; SLAM, systemic lupus activity measure index score; SLEDAI, SLE
disease activity index; VAS, visual analog scales.
1Denotes mg total dose.
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mucosal erosions 3 months after anti-
CD20 treatment. Up to now, one addi-
tional case report demonstrated a good
clinical response of otherwise resistant
paraneoplastic pemphigus, although
there are three published cases describ-
ing a lack of efficacy of anti-CD20
therapy in paraneoplastic pemphigus
due to the poor prognosis of the under-
lying malignancies (Hoque et al., 2007).
In autoimmune bullous diseases,
rituximab has been used mostly to treat
PV and PF. The clinical efficacy of
rituximab treatment is shown in a
representative PV patient (Figure 2),
and it has been described by several
cohort studies and most recently a
multicenter study using a single cycle
of rituximab in 14 PV and seven PF
patients with otherwise recalcitrant
disease (Joly et al., 2007). In this
study, anti-CD20 therapy (rituximab
4 375 mg m2) was applied in an
adjuvant setting based on systemic
glucocorticoids and adjuvant immuno-
suppressives. Eighteen of 21 patients
experienced complete remission within
3 months after rituximab therapy, and
nine patients relapsed after a mean of 19
months (Joly et al., 2007). A recent study
by Ahmed et al. (2006) combined
rituximab with high-dose intravenous
immunoglobulin (IVIG) treatment in 11
PV patients with inadequate responses to
conventional immunosuppression and
IVIG alone. During the first 2 months,
these patients received three weekly
infusions of rituximab (375 mg m2)
followed by IVIG (2 g kg1) in the fourth
week, whereas in months 3–6, rituximab
was administered once per month plus a
single infusion of 2 g kg1 of IVIG. Nine
of 11 patients experienced a complete
remission within 7–9 weeks after the first
rituximab infusion, lasting between 22
and 37 months, whereas 2 patients
showed a relapse 12 months after
beginning the study (Ahmed et al.,
2006). In this study, systemic immuno-
suppression was tapered after the
first rituximab infusion and discontinued
by the end of week 8.
Summarizing the numerous case
reports and smaller cohort studies,
more than 50 pemphigus patients have
been treated with rituximab, mostly
combined with systemic immunosup-
pressants. In most studies, rituximab
treatment led to a decrease of dsg1-/
dsg3-reactive autoantibodies correlating
well with clinical remission, although
there are reports indicating a clinical
response with persisting autoantibody
levels (Herrmann et al., 2003; Morrison,
2004). For the treatment of low-grade or
follicular CD20þ B-cell lymphoma, the
recommended dosing consists of
375 mg m2 body surface area i.v. once
weekly for four weeks. Originally, in
most studies, this oncological treatment
regimen has been adopted for the
treatment of autoimmune diseases (Ta-
ble 1). In blistering skin disorders,
rituximab is generally applied in an
adjuvant setting combined with sys-
temic immunosuppressives, including
corticosteroids, azathioprine, or myco-
phenolate mofetil (Hertl et al., 2008).
Different dosing regimens of rituximab
have successfully been applied, as
demonstrated in RA by the DANCER
study, showing that two infusions with
500 and 1,000 mg rituximab on days 1
and 15 were highly effective in the
treatment of active RA (Emery et al.,
2006). In the treatment of patients with
autoimmune blistering skin disorders,
the safety profile of rituximab is com-
parable with the results of previous
studies in RA (Edwards et al., 2004).
Aside from infusion-related adverse
events including headache, fever, chills,
urticaria, and hypotension, a number of
serious and fatal opportunistic bacterial
and viral infections have been reported,
especially in patients receiving high-
dose immunosuppressive medication
(Hertl et al., 2008). Recently, a safety
warning was announced by the FDA
regarding the development of progres-
sive multifocal leukoencephalopathy
occurring in two SLE patients treated
with rituximab (Berger, 2007).
Anti-CD22 Ab (epratuzumab). Besides
the successful use of anti-CD20 treat-
ment, other B-cell-specific surface
markers such as CD19 and CD22 have
recently become potential targets of Ab
therapy (Table 2).
CD22 represents a 135 kDa lektin-
like type I transmembrane glycoprotein
belonging to the Ig superfamily, which is
expressed at low levels on immature B
cells and at higher levels on circulating
mature IgDþ IgMþ B cells, whereas
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Figure 2. Clinical response to rituximab in pemphigus. The clinical course of a PV patient with severe
erosions of skin and oral mucosa, resistant to long-term conventional immunosuppressive medication
including high-dose prednisolone and mycophenolate mofetil is shown. Rituximab treatment lead to a
significant clinical remission reflected by a decline of the clinical score (autoimmune bullouse skin
disease intensity score (ABSIS)), which correlates with a decrease of anti-desmoglein (dsg)-3 and dsg-1
IgG titers for the entire observation period of 12 months.
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differentiated plasma cells lack CD22
expression (Tedder et al., 2005). Its
function is not completely understood,
but in addition to attenuating B-cell
receptor signaling by cytoplasmic inhi-
bitory motifs, it acts as a homing receptor
for recirculating B cells (O’Keefe et al.,
1999). Consisting of 7 immunoglobulin-
like domains, CD22 mediates adhesion
to oligosaccharides bearing a2,6-linked
sialic acid residues that are present on
most leukocytes and other serum com-
ponents (Engel et al., 1995).
Epratuzumab (hLL2), a humanized,
monoclonal IgG1 anti-CD22 Ab, binds
to the third cytoplasmic Ig domain,
inducing a rapid CD22 internalization
and phosphorylation (Carnahan et al.,
2003). In contrast to rituximab, epratu-
zumab is considered as an immuno-
modulatory agent probably engaging
the negative signaling effects of CD22
(Tedder et al., 2005). Both in non-
Hodgkin lymphoma and SLE, anti-
CD22 Ab treatment leads to a modest
(that is, 30–54%) reduction of periph-
eral B cells (Carnahan et al., 2007).
Recently, clinical studies including
open label phase II trials were con-
ducted in SLE and pSS patients. Stein-
feld et al. (2006) treated 16 pSS patients
with four infusions of 360 mg m2
epratuzumab every other week with a
6-month follow-up period. A total of
53% of the patients demonstrated a
clinically relevant response for at least
18 weeks with moderately decreased
(that is, 39–54%) circulating B cells.
Dorner et al. (2006) analyzed the
therapeutic efficacy and safety of epra-
tuzumab in 14 SLE patients, showing a
modest decline in B cells and clinical
activity score (BILAG score, British Isles
Lupus Assessment Group).
Inhibitors of survival and signaling
factors
The B-cell-activating factor and a
proliferation-inducing ligand system.
In the context of autoimmune disorders,
B-cell tolerance and homeostasis are of
major interest. Thus, factors influencing
B-cell maturation have been thoroughly
characterized in various autoimmune
Table 2. Current therapeutic strategies interfering with B-cell function in autoimmune skin diseases
Effect Target Agent Origin
Clinical evidence
level References
B-cell depletion CD20 Rituximab Chimeric human/mouse IgG1
mAb
Clinical trials (Browning, 2006; Stohl and
Looney, 2006; Dorner and
Lipsky, 2007; Arkfeld, 2008)
Ha20 (IMMU-106) Fully humanized mAb Case report in SLE (Tahir et al., 2005; Fanale and
Younes, 2007)
CD22 Epratuzumab Humanized IgG1 mAb Clinical trials
(SLE, pSS)
(Browning, 2006; Steinfeld et al.,
2006; Stohl and Looney, 2006;
Carnahan et al., 2007; Jacobi
et al., 2008)
Blocking survival
signals/growth
factor inhibition
BAFF Belimumab
(Lymphostat-B)
Fully human IgG1 mAb Clinical trials (SLE) (Baker et al., 2003; Browning,
2006; Halpern et al., 2006; Stohl
and Looney, 2006; Chatham
et al., 2008; Wallace et al., 2008)
AMG 623 ‘‘Peptidbody’’—fusion
between Fc portion of
IgG and a peptid-specific
sequence of BAFF
Clinical trials (SLE) (Stohl and Looney, 2006;
Dorner and Lipsky, 2007)
BAFF/
APRIL
IVIg (anti-BAFF
and anti-APRIL)
Polyclonal IgG selected
from healthy donors
Clinical trials
(DH, ABD)
(Le Pottier et al., 2007)
Atacicept (Taci-Ig) Recombinant human
fusion protein
Clinical trials (SLE) (Stohl and Looney, 2006; Dall’era
et al., 2007; Dorner and Lipsky,
2007; Munafo et al., 2007)
CD22 Epratuzumab Humanized IgG1 mAb Clinical trials
(SLE, pSS)
(Browning, 2006; Steinfeld et al.,
2006; Stohl and Looney, 2006;
Carnahan et al., 2007; Jacobi
et al., 2008)
Interference with
proapoptotic signals
Fas,
caspases
IVIg (anti-Fas) Polyclonal IgG, selected
from healthy donors
Clinical trials
(DH, ABD)
(Prasad et al., 1998)
Blocking immune
complex signalling
FcR, FcRn IVIg Polyclonal IgG, selected
from healthy donors
Clinical trials
(DH, ABD)
(Li et al., 2005; Browning, 2006)
Removal of serum IgG IgG Immunoadsorption
(IA)
Protein A-based adsorption
of IgG (including pathogenic
IgG) and circulating immune
complexes from plasma
Clinical trials
(ABD)
(Eming and Hertl, 2006a, b;
Shimanovich et al., 2006, 2008;
Niedermeier et al., 2007)
ABD, autoimmune bullous diseases; APRIL, a proliferation-inducing ligand; BAFF, B-cell-activating factor; DH, dermatomyositis; IVIg, intravenous
immunoglobulin; mAb, monoclonal antibody; pSS, primary Sjo¨gren’s syndrome; SLE, systemic lupus erythematosus.
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diseases (Tangye et al., 2006). The B-cell
activation factor from the tumor necrosis
family (BAFF, also known as BLyS (B
lymphocyte stimulator)) represents a key
survival factor for B-cell development,
whose complex function for B-cell toler-
ance is not completely defined yet
(Mackay et al., 2003; Schneider, 2005).
There are three different BAFF receptors:
B-cell maturation antigen (BCMA); trans-
membrane activator and calcium mod-
ulator and cyclophilin ligand interactor
(TACI); and BAFF receptor (BAFF-R), of
which BCMA and TACI are shared with
another ligand of the TNF family, a
proliferation-inducing ligand (APRIL).
Both BAFF and APRIL are expressed
mainly by monocytes, macrophages,
and dendritic cells, to a lesser extent by
T cells, and also by nonlymphoid cells
such as epithelial cells, stromal bone
marrow cells, and synoviocytes (Mackay
et al., 2007). Depending on the state of
maturation, B cells express BAFF-R,
BCMA, and TACI in different intensities,
whereas BAFF-R is also expressed by
activated and regulatory T cells. BCMA
has been identified on plasma cells and
plasma blasts (Mackay et al., 2007).
Chang et al. (2006) found TACI expres-
sion on activated human macrophages,
suggesting a role for BAFF in innate
immunity. The complex physiological
network of the BAFF/APRIL system goes
beyond the scope of this review and is
extensively discussed elsewhere. In the
following paragraphs, we will parti-
cularly focus on the recent understanding
of the role of BAFF and APRIL in B-cell-
mediated autoimmunity.
BAFF/APRIL in autoimmune disease.
Numerous studies in SLE, RA, and pSS
consistently found increased levels of
BAFF (Figure 3), APRIL, and even BAFF/
APRIL heterotrimers in serum and target
tissues, strengthening the pathogenic
relevance of raised BAFF and APRIL,
respectively (Pers et al., 2005; Seyler
et al., 2005). Moreover, in pSS, SLE,
and RA, elevated BAFF and/or APRIL
serum levels correlate with autoanti-
body titers and/or disease activity in
some patients (Cheema et al., 2001;
Zhang et al., 2001; Jonsson et al., 2005;
Schaller et al., 2005). Asashima et al.
(2006) recently reported increased
BAFF serum levels in patients with
bullous pemphigoid but not in patients
with PV. In a recent study by Matsush-
ita et al., BAFF serum levels were
investigated in patients with localized
scleroderma, bullous pemphigoid and
PF/PV (Matsushita et al., 2007b). In this
study, 32% (14/44) of patients with
localized scleroderma showed in-
creased BAFF serum levels compared
with healthy controls. Moreover, the
authors found a correlation between
BAFF serum levels and disease severity,
as 53% of the patients with generalized
scleroderma, 27% with morphea, and
13% with linear scleroderma exhibited
elevated BAFF serum levels (Matsushita
et al., 2007b). BAFF serum levels of
patients with bullous pemphigoid and
PF/PV were not significantly increased
compared with healthy controls. A
previous study by the same group
investigated serum BAFF levels, BAFF
mRNA in skin samples, and the expres-
sion of BAFF-R on peripheral B cells in
83 patients with SSc (Matsushita et al.,
2006). Compared with healthy indivi-
duals, BAFF serum levels in SSc
patients were elevated and correlated
with the extent of the disease. Further-
more, BAFF-R expression on CD19þ
peripheral B cells was increased in SSc,
as was BAFF mRNA expression found
in biopsies of lesional skin (Matsushita
et al., 2006).
BAFF has been shown to play an
important role in maintaining B-cell
tolerance, as autoreactive B-cell clones
show an impaired ability to respond to
limited levels of BAFF leading to their
depletion (Brink, 2006). On the other
hand, strongly elevated serum levels
of BAFF might propagate autoreactive
B-cell clones by rescuing them from
deletion (Thien et al., 2004).
Rituximab
(anti-CD20)
mAb
SLE, pSS, SSc, BP,
ANCA-associated vasculitis 
BAFF
CD25
BAFF-R
TACI
BCMA
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Figure 3. Rituximab exerts various immune functions by the induction of BAFF. BAFF is overexpressed in many autoimmune diseases like SLE, pSS, SSc,
bullous pemphigoid (BP), and different antineutrophil cytoplasmatic Ab (ANCA)-associated vasculitides. Furthermore, the generation and release of BAFF is
increased after rituximab-induced B-cell depletion. By binding to its receptors BAFF-R, BCMA, and TACI, which are expressed on a variety of different
lymphocyte subsets, BAFF exerts a central role in regulating immune responses. BAFF supports the de novo generation and survival of B lymphocytes and
stimulates the survival of long-lived bone-marrow plasma cells (PC). Furthermore, BAFF increases the expression of CD25 on CD4þ Th cells as well as the
release of TNF-a and interferon-g by these cells (Huard et al., 2001). Moreover, it has a promoting effect on the proliferation and survival of naturally occuring
CD4þCD25þ regulatory T cells (TReg) (Ye et al., 2004; Schneider, 2005). Therapeutic administration of BAFF antagonists or intravenous immunoglobulin (IVIg)
interferes with these different effects of BAFF.
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BAFF/APRIL in animal models of
autoimmune diseases. The effect of
elevated BAFF serum levels on self-
reactive immune responses has been
investigated using mouse models of
various autoimmune diseases. BAFF-
transgenic mice develop a phenotype
resembling typical symptoms of human
autoimmune disorders, including the
presence of circulating immune com-
plexes, immunoglobulin deposition in
the kidneys, anti-DNA autoantibodies,
and the presence of rheumatoid factors
(Mackay et al., 1999).
In a recent study, Matsushita et al.
(2007a) investigated the role of BAFF in
tight-skin mice, an animal model of
SSc. The authors found elevated BAFF
serum levels in these mice until 8
weeks of age compared with wild-type
littermates, whereas no significant dif-
ferences in expression of BAFF-R,
BCMA, or TACI were noticed. Further-
more, neutralizing BAFF by treating
tight-skin mice with BAFF-R-Ig reduced
the development of skin fibrosis, de-
creased the production of anti-topoi-
somerase I antibodies, and attenuated
the expression of IL-6 and IL-10,
whereas it upregulated interferon-g
production in the skin of these animals
(Matsushita et al., 2007a).
Effect of rituximab treatment on BAFF
and APRIL in autoimmune diseases.
Numerous recent studies demonstrated
increased serum BAFF levels upon
peripheral B-cell depletion by rituximab
treatment in RA, SLE, and pSS (Vallers-
kog et al., 2006; Seror et al., 2007).
A recent study by Nagel et al. (Nagel,
A, Podstawa E, Eickmann M, Hertl M,
Eming R, Rituximab mediates a strong
elevation of B cell activating factor
(BAFF) associated with increased patho-
gen-specific IgG but not anti-bodies in
pemphigus vulgaris, submitted) investi-
gated BAFF and APRIL serum levels in 11
PV patients following rituximab therapy,
compared with PV patients treated with
immunosuppression and immunoadsorp-
tion. Immunosuppressive therapy and
adjuvant immunoadsorption altered
neither BAFF nor APRIL serum levels,
whereas rituximab induced a significant
increase in BAFF levels as long as
peripheral B-cell depletion persisted.
Moreover, whereas anti-dsg1- and anti-
dsg3-IgG autoantibodies decreased, the
titers of pathogen-specific IgG (anti-
varicella-zoster-virus-IgG, anti-Epstein–-
Barr virus-IgG) were transiently increased
6 months after rituximab therapy, prob-
ably due to elevated BAFF levels enfor-
cing Ab secretion by long-lived plasma
cells. Of note, anti-CD20 Ab treatment
did not affect APRIL serum levels, which
remained unchanged in all 11 PV
patients investigated (Nagel et al., sub-
mitted; cited above).
Therapeutic manipulation of B-cell
survival factors. The concept that im-
paired expression of BAFF and an
imbalance of the BAFF/APRIL system
enforce the development and matura-
tion of autoreactive B-cell clones led to
the development of new, BAFF-direc-
ted therapeutic approaches.
Animal models: A study by Rama-
nujam et al. (2006) investigated the
effect of selective and nonselective
BAFF blockade in a murine model of
SLE (NZB/NZW F1 mice), demon-
strating that both BAFF-R-Ig and TACI-
Ig fusion proteins delayed the onset of
SLE and improved mortality in this
model. Both treatment regimens re-
duced the numbers of activated and
memory T-cell subsets and induced
comparable depletion of marginal zone
and follicular B cells. In contrast to
selective inhibition of BAFF by BAFF-R-
Ig, blockade of BAFF and APRIL by
TACI-Ig reduced serum IgM levels and,
most strikingly, decreased the number
of splenic plasma cells (Ramanujam
et al., 2006). Whether the absence of
BAFF can prevent the de novo onset of
an autoantibody-mediated disease has
been addressed by developing BAFF-
deficient New Zealand Mixed mice
(Jacob et al., 2006). In contrast to
BAFF-competent New Zealand Mixed
mice, BAFF-deficient animals demon-
strated reduced germinal centers as
well as lower numbers of Ig-secreting
cells and T cells (Jacob et al., 2006).
Interestingly, at the age of 10–13
months, these mice showed serum Ig
autoantibody levels (i.e., anti-histone-
IgG and anti-ds-DNA-IgG) that reached
wild-type levels, suggesting that auto-
reactive B cells are able to survive and
produce autoantibodies in the absence
of BAFF. Although BAFF-deficient
New Zealand Mixed mice were not
protected from autoantibody produc-
tion, renal pathology and clinical
symptoms such as proteinuria were
attenuated compared with BAFF-com-
petent littermates, probably due to the
skewed autoantibody profile in which
IgG1 autoantibodies are the predomi-
nating isotype in BAFF-deficient
animals (Jacob et al., 2006).
Clinical trials: Belimumab (Lympho-
Stat-B) is a fully human IgG1l anti-
BAFF mAb that targets soluble BAFF
and has demonstrated modest efficacy
in recent phase I/II studies in SLE and
RA. Anti-BAFF therapy significantly
reduces the number of activated
CD69þ peripheral B cells in clinically
responsive SLE patients, exhibiting few
adverse effects (Stohl et al., 2006). A
total of 449 patients with active SLE
were enrolled in a phase II, rando-
mized, double-blind, placebo-con-
trolled trial with belimumab (1, 4, and
10 mg kg1) in addition to standard
immunosuppressive therapy for 52
weeks, followed by 1.5 years of open-
label belimumab treatment. Belimumab
treatment normalized hypergamma-
globulinemia and reduced anti-dsDNA,
anti-Sm and anti-RNP autoantibody
levels compared with the placebo con-
trol group (Chatham et al., 2008). Other
approaches using BAFF receptor-Ig
fusion protein (BR3-Ig) or a decoy
receptor, TACI-Ig, are currently being
explored. The possible impact of
therapeutic administration of BAFF
antagonists on immune cells is
summarized in Figure 3.
FUTURE PERSPECTIVES
The various mechanisms by which
B cells are involved in the induction
and maintenance of autoimmune
diseases are intensively investigated.
In dermatology, the various functions
of autoreactive B cells including T-cell
activation via antigen presentation,
secretion of proinflammatory cyto-
kines, and production of self-reactive
antibodies are increasingly appreciated
in the treatment of autoimmune bullous
disorders, SLE, dermatomyositis, SSc,
and vasculitides. The use of the
anti-CD20 Ab rituximab in severe
pemphigus is its most familiar
clinical application, while its use in
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inflammatory disorders such as derma-
tomyositis, atopic dermatitis, chronic
graft-versus-host disease and different
vasculitides including anti-neutrophil
cyctoplasmic Ab-associated vasculitides
awaits further analysis. In contrast to
extensive use in SLE, cutaneous lupus
erythematous has not been treated with
rituximab. Recent studies have evalu-
ated fully humanized anti-CD20 mAbs
that are expected to be less antigenic
than rituximab (Genovese et al., 2006).
Currently, the clinical effectiveness of
targeting the B-cell survival factors BAFF
and APRIL is being investigated in RA,
SLE, and pSS. Furthermore, blockade of
the CD40-CD40L interaction as well as
neutralizing different cytokines such as
IL-6, IL-21, and TNF-a, which are of
importance for B-cell activation and
differentiation, are being discussed as
potential targets for innovative therapies
in autoimmune disorders.
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